Yiling Pharmaceutical (002603.SZ) subsidiary's drug clinical trial application for Jianggu Guanjie Granules accepted

Zhitong Finance APP News, Yiling Pharmaceutical (002603.SZ) announced that its wholly-owned subsidiary Beijing Yiling Pharmaceutical Co., Ltd. received the "Notice of Acceptance" approved and issued by the National Medical Products Administration on October 21, 2026, and the new drug clinical trial application for Jiangu Joint Granules has been accepted. The proposed functions and indications of Jiangu Joint Granules are: tonifying the kidney and strengthening bones, promoting blood circulation and dredging collaterals, and relaxing sinews and relieving pain.